Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials

Critical Reviews in Oncology/Hematology

Volumn 87, Issue 1, 2013, Pages 80-89

  Sonpavde, Guru ^a   Je, Youjin ^b   Schutz, Fabio ^c   Galsky, Matthew D ^d   Paluri, Ravikumar ^a   Rosenberg, Jonathan E ^e   Bellmunt, Joaquim ^f   Choueiri, Toni K ^g  

^a University of Alabama at Birmingham   (United States)

^b Kyung Hee University   (South Korea)

^c HOSPITAL SÃO JOSÉ   (Brazil)

^d Mount Sinai Tisch Cancer Institute   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f HOSPITAL DEL MAR   (Spain)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Approved; Meta analysis; Tyrosine kinase inhibitors; Vascular endothelial growth factor receptor; Venous thromboembolic events

Indexed keywords

AXITINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; INTERFERON; LAPATINIB; PACLITAXEL; PAZOPANIB; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR;

BREAST CANCER; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; EMBOLISM; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MELANOMA; META ANALYSIS; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; RISK FACTOR; SCORING SYSTEM; STATISTICAL ANALYSIS; STUDY DESIGN; SUPERFICIAL VENOUS THROMBOSIS; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; THROMBOSIS; THROMBUS; UTERINE CERVIX CANCER; VEIN EMBOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK; VENOUS THROMBOEMBOLISM;

EID: 84878602173     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.12.006     Document Type: Review

References (43)

1. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010, 28:2280-2285.
2. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute 2007, 99:1232-1239.
3. Hurwitz H.I., Saltz L.B., Van Cutsem E., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. Journal of Clinical Oncology 2011, 29:1757-1764.
4. Nalluri S.R., Chu D., Keresztes R., Zhu X., Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA: Journal of the American Medical Association 2008, 300:2277-2285.
5. Chu D., Wu S. Risk of venous thromboembolism with bevacizumab in cancer patients: reply. JAMA: Journal of the American Medical Association 2009, 301:1435-1436.
6. Schutz F.A., Richards J., Je Y., Bellmunt J., Choueiri T.K. Risk of venous thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Genitourinary Cancer Symposium 2010, [abstract 348].
7. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996, 17:1-12.
8. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009, 62:e1-e34.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986, 7:177-188.
10. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. British Medical Journal 2003, 327:557-560.
11. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
12. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
13. Monk B.J., Mas Lopez L., Zarba J.J., et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology 2010, 28:3562-3569.
14. Horti J., Widmark A., Stenzl A., et al. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biotherapy and Radiopharmaceuticals 2009, 24:175-180.
15. Rugo H.S., Stopeck A.T., Joy A.A., et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. Journal of Clinical Oncology 2011, 29:2459-2465.
16. Herbst R.S., Sun Y., Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncology 2010, 11:619-626.
17. Arnold A.M., Seymour L., Smylie M., et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical Oncology 2007, 25:4278-4284.
18. Heymach J.V., Paz-Ares L., De Braud F., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology 2008, 26:5407-5415.
19. Kindler H.L., Ioka T., Richel D.J., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncology 2011, 12:256-262.
20. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
21. Hauschild A., Agarwala S.S., Trefzer U., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. Journal of Clinical Oncology 2009, 27:2823-2830.
22. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon Alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2009, 27(22):3584-3590.
23. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon Alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 2007, 356:115-124.
24. Scagliotti G., Novello S., von Pawel J., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:1835-1842.
25. Abou-Alfa G.K., Johnson P., Knox J.J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA: Journal of the American Medical Association 2010, 304:2154-2160.
26. Krege S., Rexer H., vom Dorp F., et al. Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). Journal of Clinical Oncology 2010, 28(Suppl.):15s. [abstract 4574].
27. Michaelson M.D., Oudard S., Ou Y., et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2011, 29(Suppl.). [abstract 4515].
28. Lee J.S., Hirsh V., Park K., et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). Journal of Clinical Oncology 2012, 30:1114-1121.
29. Ward J.E., Karrison T., Chatta G., et al. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer and Prostatic Diseases 2012, 15:87-92.
30. van der Graaf W.T., Blay J.Y., Chawla S.P., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.
31. Murthy V.H., Krumholz H.M., Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA: Journal of the American Medical Association 2004, 291:2720-2726.
32. Khorana A.A., Kuderer N.M., Culakova E., Lyman G.H., Francis C.W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008, 111:4902-4907.
33. Stone J.R., Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002, 9:231-238.
34. Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovascular Research 2001, 49:568-581.
35. 2. American Journal of Physiology - Heart and Circulatory Physiology 2006, 291:H1395-H1401.
36. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer 2007, 96:1788-1795.
37. Zangari M., Fink L.M., Elice F., Zhan F., Adcock D.M., Tricot G.J. Thrombotic events in patients with cancer receiving antiangiogenesis agents. Journal of Clinical Oncology 2009, 27:4865-4873.
38. Schutz F.A., Je Y., Choueiri T.K. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology 2011, 80:291-300.
39. Schutz F.A., Choueiri T.K., Sternberg C.N. Pazopanib: clinical development of a potent anti-angiogenic drug. Critical Reviews in Oncology/Hematology 2011, 77:163-171.
40. Schutz F.A., Je Y., Azzi G.R., Nguyen P.L., Choueiri T.K. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology 2011, 22:1404-1412.
41. Ranpura V., Hapani S., Chuang J., Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncologica 2010, 49:287-297.
42. Mandala M., Clerici M., Corradino I., et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Annals of Oncology 2012, 23:1416-1421.
43. Cooper H., Hedges L. The handbook of research synthesis 1994, Russell Sage, New York.